Angela Alfano

Angela Alfano

Auto-generated profile, based on publicly available information

Angela Alfano

Dermatology Unit IRCCS Humanitas Research Hospital Rozzano Italy

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 August 2025 in Australasian Journal of Dermatology
Verified
Journal Article
Open access
RIRuggero Cascio Ingurgio
Ruggero Cascio Ingurgio
AAA. Alfano
A. Alfano
EME. Matteodo
E. Matteodo
MSM. Stark
M. Stark
MVM. Valenti
M. Valenti
Dedee MurrellDedee Murrell
Dedee Murrell
Background: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with systemic implications. While biologic therapies have demonstrated efficacy in controlling cutaneous lesions, their systemic effects, particularly on lipid metabolism as a marker of systemic inflammation, are less understood. Objectives: To evaluate the impact of biologic therapy on clinical severity and lipid profiles in HS patients in a real‐world setting, comparing outcomes between Early and Late Responders at Week 24 ± 4. Methods: Twenty‐four patients with moderate‐to‐severe HS on biologic therapy were monitored prospectively at Baseline, Week 24 ± 4, Week 52 and Week 104. Clinical parameters (IHS4, A/N, HS‐IGA) and lipid profiles (cholesterol, triglycerides) were analysed. Patients were categorised as Early (IHS4 ≤ 10) or Late Responders (IHS4 ≥ 11) at Week 24 ± 4. Statistical analysis included t ‐tests; significance was set at p < 0.05. Results: Early Responders showed significant clinical improvement and reductions in lipid levels, suggesting a systemic anti‐inflammatory effect of therapy. However, lipid reductions did not reach statistical significance ( p > 0.05); likely due to the small sample size. Late Responders demonstrated less pronounced changes. Conclusions: Biologic therapy appears to improve both clinical and systemic inflammatory markers in HS, highlighting the value of metabolic monitoring in routine care.

17 April 2025 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
Luigi GargiuloLuigi Gargiulo
Luigi Gargiulo
SFSilvia M. Ferrucci
Silvia M. Ferrucci
Luciano IbbaLuciano Ibba
Luciano Ibba
RIRuggero Cascio Ingurgio
Ruggero Cascio Ingurgio
AAAngela Alfano
Angela Alfano
ANAlessandra Narcisi
Alessandra Narcisi

13 January 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
RIRuggero Cascio Ingurgio
Ruggero Cascio Ingurgio
AAAngela Alfano
Angela Alfano
EMElena Matteodo
Elena Matteodo
Luciano IbbaLuciano Ibba
Luciano Ibba
Luigi GargiuloLuigi Gargiulo
Luigi Gargiulo
Mario ValentiMario Valenti
Mario Valenti
Background: Psoriasis involving difficult-to-treat anatomical areas, such as the scalp, genitalia, fingernails, and palmoplantar regions, carries a disproportionate disease burden and often requires systemic therapy. In this context, real-life data comparing the long-term effectiveness of tildrakizumab 100 mg versus 200 mg in patients with difficult-to-treat psoriasis remain limited. Methods: This multicenter retrospective observational study included adult patients in three Italian dermatology centers. Global efficacy endpoints included PASI75, PASI90, PASI100, and absolute PASI ≤ 2 at weeks 16, 32, 52, and 104. Site-specific effectiveness was assessed as complete clearance (PGA = 0) in patients with baseline involvement (PGA ≥ 2) of difficult-to-treat areas. Outcomes were described by dose. Results: 183 patients were included (100 mg: n = 89; 200 mg: n = 94). Patients receiving 200 mg had higher baseline BMI and were more frequently biologic-experienced. At week 104, PASI75 was achieved by 94.2% of patients receiving 100 mg and 94.7% receiving 200 mg, while PASI90 and PASI100 were achieved by 82.7% vs. 57.9% and 48.1% vs. 47.4%, respectively. Clearance of difficult-to-treat areas improved progressively across all sites. Scalp and genital psoriasis showed higher and earlier clearance rates, whereas nail and palmoplantar psoriasis showed slower and more heterogeneous responses. No consistent dose-dependent advantage emerged, despite less favorable baseline characteristics in the 200 mg group. Conclusions: Over 104 weeks, tildrakizumab showed sustained long-term effectiveness in both global disease control and difficult-to-treat areas. The 200 mg dose, used in a more difficult-to-treat population, achieved comparable long-term outcomes, supporting dose optimization in clinical practice.

29 May 2025 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
RBRiccardo Balestri
Riccardo Balestri
GOGiulia Odorici
Giulia Odorici
MMMichela Magnano
Michela Magnano
PGPaolo Gisondi
Paolo Gisondi
FBFrancesco Bellinato
Francesco Bellinato
GRGiulia Rech
Giulia Rech

27 May 2025 in Australasian Journal of Dermatology
Verified
Journal Article
Open access
RIRuggero Cascio Ingurgio
Ruggero Cascio Ingurgio
AAA. Alfano
A. Alfano
Luigi GargiuloLuigi Gargiulo
Luigi Gargiulo
Luciano IbbaLuciano Ibba
Luciano Ibba
ANA. Narcisi
A. Narcisi
Dedee MurrellDedee Murrell
Dedee Murrell
Background: Pyoderma gangrenosum (PG) is a challenging inflammatory skin disorder. While corticosteroids offer a rapid response, their long‐term risks necessitate alternative treatments.Objective: To compare the long‐term effectiveness of biologic therapies versus systemic corticosteroids in PG management.Methods: A retrospective analysis of 15 PG patients from two centres (Sydney, Australia, and Milan, Italy) was conducted. Patients received either biologic therapies (n = 8) or corticosteroids (n = 7), with ulcer healing outcomes assessed at weeks 16, 28–32 and 54.Results: At week 16, corticosteroids led to faster ulcer reduction and re‐epithelialisation. However, biologic‐treated patients showed sustained improvement over time, supporting their role in long‐term PG management.Conclusion: While corticosteroids provide an initial advantage, biologics demonstrate gradual and sustained efficacy, suggesting a long‐term therapeutic role in PG treatment.

8 September 2026 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
PDF file
RIRuggero Cascio Ingurgio
Ruggero Cascio Ingurgio
AAAngela Alfano
Angela Alfano
ACAntonio Costanzo
Antonio Costanzo
JCJulie S. Cronk
Julie S. Cronk
RCRebecca Cummins
Rebecca Cummins
Dedee MurrellDedee Murrell
Dedee Murrell